ULTRAGENYX PHARMACEUTICAL IN (RARE:NASDAQ)
$22.41 0.63 (2.8926%)
Analysed ULTRAGENYX PHARMACEUTICAL IN (RARE:NASDAQ) News Sources
Ultragenyx (RARE) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
05-05-2026
yahoo.com
Ultragenyx Pharmaceutical Q1 Earnings Call Highlights
06-05-2026
marketbeat.com
Ultragenyx Pharmaceutical Inc. Q1 2026 Earnings Call Summary
06-05-2026
moby.co
RARE Q1 Loss Wider Than Expected, Sales Down Y/Y on Seasonal Effect
06-05-2026
yahoo.com
Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference
06-05-2026
yahoo.com
Is Ultragenyx (RARE) Reaffirming 2026–2027 Guidance Enough To Offset Its Widening Losses?
11-05-2026
yahoo.com
Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
12-05-2026
yahoo.com
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
22-05-2026
yahoo.com
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year
30-05-2026
fool.com
Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference
03-06-2026
yahoo.com
What is the current price of ULTRAGENYX PHARMACEUTICAL IN (RARE:NASDAQ)?
The current price of ULTRAGENYX PHARMACEUTICAL IN (RARE:NASDAQ) is $22.41.
ULTRAGENYX PHARMACEUTICAL IN (RARE:NASDAQ) absolute price change since previous trading day?
The absolute price change of ULTRAGENYX PHARMACEUTICAL IN (RARE:NASDAQ) since the previous trading day is $0.63.
ULTRAGENYX PHARMACEUTICAL IN (RARE:NASDAQ) percentage price change since previous trading day?
The percentage price change of ULTRAGENYX PHARMACEUTICAL IN (RARE:NASDAQ) since the previous trading day is 2.8926%.
What is the most recent average sentiment score for ULTRAGENYX PHARMACEUTICAL IN (RARE:NASDAQ)?
The most recent average sentiment score for ULTRAGENYX PHARMACEUTICAL IN (RARE:NASDAQ) is 64 out of 100.
What is the most recent average sentiment for ULTRAGENYX PHARMACEUTICAL IN (RARE:NASDAQ)?
The most recent sentiment for ULTRAGENYX PHARMACEUTICAL IN (RARE:NASDAQ) is .
SEC-8K** Filing Available For ULTRAGENYX PHARMACEUTICAL IN (RARE:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.